These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16401804)

  • 1. The PSA Conundrum.
    Barry MJ
    Arch Intern Med; 2006 Jan; 166(1):7-8. PubMed ID: 16401804
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate-specific antigen and screening for prostate cancer.
    Han M; Gann PH; Catalona WJ
    Med Clin North Am; 2004 Mar; 88(2):245-65, ix. PubMed ID: 15049577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What can be concluded from the ERSPC and PLCO trial data?
    Studer UE; Collette L
    Urol Oncol; 2010; 28(6):668-9. PubMed ID: 21062648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of screening for prostate cancer: a nested case-control study.
    Concato J; Wells CK; Horwitz RI; Penson D; Fincke G; Berlowitz DR; Froehlich G; Blake D; Vickers MA; Gehr GA; Raheb NH; Sullivan G; Peduzzi P
    Arch Intern Med; 2006 Jan; 166(1):38-43. PubMed ID: 16401808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the PSA test useless?
    Kirby R; Moul JW
    Prostate Cancer Prostatic Dis; 2004; 7(4):271-2. PubMed ID: 15592438
    [No Abstract]   [Full Text] [Related]  

  • 7. PSA and prostate cancer screening: the challenge of the new millennium.
    Bjartell A
    Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
    [No Abstract]   [Full Text] [Related]  

  • 8. PSA screening.
    Cohen S; Schiff S; Kelty P
    Med Health R I; 2005 Mar; 88(3):90-1. PubMed ID: 15915782
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cruciferous vegetables and prostate cancer risk: confounding by PSA screening.
    Kristal AR; Stanford JL
    Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1265. PubMed ID: 15247142
    [No Abstract]   [Full Text] [Related]  

  • 11. Celebrating the death of PSA screening?
    Gomella LG
    Can J Urol; 2011 Dec; 18(6):5987. PubMed ID: 22166323
    [No Abstract]   [Full Text] [Related]  

  • 12. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

  • 13. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new in prostate cancer screening and prevention?
    Klein EA
    Cleve Clin J Med; 2009 Aug; 76(8):439-45. PubMed ID: 19652036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Terris MK
    Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate specific antigen (PSA)-based screening.
    Suzuki H; Flanigan RC; Okuyama A;
    Int J Urol; 2008 Sep; 15(9):757-62. PubMed ID: 18786202
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.
    Loeb S; Carter HB
    Urol Oncol; 2009; 27(6):583-4. PubMed ID: 19879470
    [No Abstract]   [Full Text] [Related]  

  • 19. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer update: 2005.
    Ryan CJ; Small EJ
    Curr Opin Oncol; 2006 May; 18(3):284-8. PubMed ID: 16552242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.